Logo image of NYXH.BR

NYXOAH SA (NYXH.BR) Stock Fundamental Analysis

EBR:NYXH - Euronext Brussels - BE0974358906 - Common Stock - Currency: EUR

9.24  -0.12 (-1.28%)

Fundamental Rating

3

Taking everything into account, NYXH scores 3 out of 10 in our fundamental rating. NYXH was compared to 60 industry peers in the Health Care Equipment & Supplies industry. While NYXH seems to be doing ok healthwise, there are quite some concerns on its profitability. NYXH is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NYXH had negative earnings in the past year.
NYXH had a negative operating cash flow in the past year.
In the past 5 years NYXH always reported negative net income.
NYXH had a negative operating cash flow in each of the past 5 years.
NYXH.BR Yearly Net Income VS EBIT VS OCF VS FCFNYXH.BR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M -40M

1.2 Ratios

NYXH's Return On Assets of -37.11% is on the low side compared to the rest of the industry. NYXH is outperformed by 80.00% of its industry peers.
NYXH has a Return On Equity of -50.60%. This is in the lower half of the industry: NYXH underperforms 69.09% of its industry peers.
Industry RankSector Rank
ROA -37.11%
ROE -50.6%
ROIC N/A
ROA(3y)-24.12%
ROA(5y)-27.74%
ROE(3y)-29.54%
ROE(5y)-65.78%
ROIC(3y)N/A
ROIC(5y)N/A
NYXH.BR Yearly ROA, ROE, ROICNYXH.BR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 -50 -100 -150 -200

1.3 Margins

The Gross Margin of NYXH (61.75%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of NYXH has grown nicely.
The Profit Margin and Operating Margin are not available for NYXH so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.75%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.08%
GM growth 5YN/A
NYXH.BR Yearly Profit, Operating, Gross MarginsNYXH.BR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

NYXH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NYXH has been increased compared to 1 year ago.
NYXH has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NYXH is higher compared to a year ago.
NYXH.BR Yearly Shares OutstandingNYXH.BR Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M 25M
NYXH.BR Yearly Total Debt VS Total AssetsNYXH.BR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

NYXH has an Altman-Z score of 2.99. This is not the best score and indicates that NYXH is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.99, NYXH is doing good in the industry, outperforming 70.91% of the companies in the same industry.
NYXH has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.21, NYXH is doing good in the industry, outperforming 70.91% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 2.99
ROIC/WACCN/A
WACC7.51%
NYXH.BR Yearly LT Debt VS Equity VS FCFNYXH.BR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

NYXH has a Current Ratio of 5.28. This indicates that NYXH is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 5.28, NYXH belongs to the top of the industry, outperforming 96.36% of the companies in the same industry.
A Quick Ratio of 4.95 indicates that NYXH has no problem at all paying its short term obligations.
NYXH has a better Quick ratio (4.95) than 98.18% of its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 4.95
NYXH.BR Yearly Current Assets VS Current LiabilitesNYXH.BR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 50M 100M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for NYXH have decreased by -2.14% in the last year.
Looking at the last year, NYXH shows a very strong growth in Revenue. The Revenue has grown by 32.65%.
Measured over the past years, NYXH shows a very strong growth in Revenue. The Revenue has been growing by 297.94% on average per year.
EPS 1Y (TTM)-2.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.47%
Revenue 1Y (TTM)32.65%
Revenue growth 3Y297.94%
Revenue growth 5YN/A
Sales Q2Q%29.71%

3.2 Future

NYXH is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 0.51% yearly.
The Revenue is expected to grow by 135.08% on average over the next years. This is a very strong growth
EPS Next Y-9.57%
EPS Next 2Y-6.59%
EPS Next 3Y0.51%
EPS Next 5YN/A
Revenue Next Year24.94%
Revenue Next 2Y152.69%
Revenue Next 3Y151.63%
Revenue Next 5Y135.08%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NYXH.BR Yearly Revenue VS EstimatesNYXH.BR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M
NYXH.BR Yearly EPS VS EstimatesNYXH.BR Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NYXH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NYXH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NYXH.BR Price Earnings VS Forward Price EarningsNYXH.BR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NYXH.BR Per share dataNYXH.BR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.59%
EPS Next 3Y0.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NYXH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NYXOAH SA

EBR:NYXH (3/7/2025, 7:00:00 PM)

9.24

-0.12 (-1.28%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-13 2025-03-13/amc
Inst Owners32.66%
Inst Owner ChangeN/A
Ins Owners20.26%
Ins Owner ChangeN/A
Market Cap345.85M
Analysts81.43
Price Target14.68 (58.87%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.42%
Min EPS beat(2)-3.56%
Max EPS beat(2)0.72%
EPS beat(4)3
Avg EPS beat(4)0.17%
Min EPS beat(4)-3.56%
Max EPS beat(4)2.33%
EPS beat(8)4
Avg EPS beat(8)-11.67%
EPS beat(12)7
Avg EPS beat(12)-3.29%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-33%
Min Revenue beat(2)-55.92%
Max Revenue beat(2)-10.09%
Revenue beat(4)1
Avg Revenue beat(4)-17.48%
Min Revenue beat(4)-55.92%
Max Revenue beat(4)4.47%
Revenue beat(8)1
Avg Revenue beat(8)-28.22%
Revenue beat(12)1
Avg Revenue beat(12)-36.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.77%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-10.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 68.05
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 6.27
EV/EBITDA N/A
EPS(TTM)-1.72
EYN/A
EPS(NY)-1.76
Fwd EYN/A
FCF(TTM)-1.33
FCFYN/A
OCF(TTM)-1.3
OCFYN/A
SpS0.14
BVpS2.8
TBVpS1.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.11%
ROE -50.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.75%
FCFM N/A
ROA(3y)-24.12%
ROA(5y)-27.74%
ROE(3y)-29.54%
ROE(5y)-65.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.08%
GM growth 5YN/A
F-Score2
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 35.42%
Cap/Sales 18.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 4.95
Altman-Z 2.99
F-Score2
WACC7.51%
ROIC/WACCN/A
Cap/Depr(3y)80.06%
Cap/Depr(5y)68.52%
Cap/Sales(3y)86.21%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.47%
EPS Next Y-9.57%
EPS Next 2Y-6.59%
EPS Next 3Y0.51%
EPS Next 5YN/A
Revenue 1Y (TTM)32.65%
Revenue growth 3Y297.94%
Revenue growth 5YN/A
Sales Q2Q%29.71%
Revenue Next Year24.94%
Revenue Next 2Y152.69%
Revenue Next 3Y151.63%
Revenue Next 5Y135.08%
EBIT growth 1Y-18.52%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.88%
EBIT Next 3Y-6.85%
EBIT Next 5Y7.62%
FCF growth 1Y-88%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.38%
OCF growth 3YN/A
OCF growth 5YN/A